Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients - REMAIN Study

NCT07363252 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.

NCT NCT07363252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07363252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients - REMAIN Study
Lead sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Phase
Observational
Overall status
Recruiting
Start date
April 14, 2026
Completion date
December 31, 2028
Enrollment
100 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

egfr-mutated nsclc